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Abstract
Purpose Dronedarone is a novel multichannel blocker with
antiadrenergic and vasodilatory properties. The aim of this
study was to investigate the effects of dronedarone on
functional capacity in patients with severe left ventricular
(LV) dysfunction and compensated stable heart failure (HF).
Methods This was a multicentre, double-blind, randomized,
placebo-controlled, dose-escalating study. Patients in sinus
rhythm with impaired LV function (LV ejection fraction
[LVEF]≤30%) and compensated HF (New York Heart
Association [NYHA] class I–II), who would continue to
receive cardiovascular treatment (excluding antiarrhythmic
agents), were eligible. A total of 124 patients were randomized
to receive dronedarone (400 mg or 800 mg once daily or
600 mg twice daily) or placebo for 30 days. The primary
objective was assessment of the effects of dronedarone
on functional capacity, using the 6 min walk test.
Secondary objectives included the effects of dronedar-
one on LVEF, cardiothoracic ratio, NYHA status, and
Holter parameters.
Results A total of 111 patients completed the study. There
were no significant differences between dronedarone and
placebo with respect to walking distance and LVEF. The
cardiothoracic ratio was similar in all treatment groups
throughout the study, and the NYHA status did not change
in the majority of patients. Dronedarone was well tolerated
and, as expected, decreased heart rate. No new arrhythmic
events or torsades de pointes were reported.
Conclusions Short-term treatment with dronedarone did not
affect exercise capacity and did not decrease LVEF in
patients with severe LV dysfunction and compensated HF.
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Introduction
Atrial fibrillation (AF) is the most common arrhythmia in
clinical practice [1] and a major cause of morbidity and
mortality [2–5]. Dronedarone is a novel multichannel
blocker with antiadrenergic and vasodilatory properties that
was developed for the treatment of patients with AF [6–8].
Dronedarone is effective in maintaining sinus rhythm
and reducing the ventricular rate in patients with paroxys-
mal and persistent AF [9, 10]. A 25% to 55% reduction in
the risk of recurrence of AF or atrial flutter was observed
with dronedarone compared with placebo in several large
controlled studies [9, 10]. Dronedarone also reduced
ventricular rate during AF in these trials. In the ERATO
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ventricular rate during atrial fibrillation) trial, dronedarone
significantly reduced the mean heart rate during submaxi-
mal and maximal exercise without decreasing exercise
duration in patients with permanent AF receiving standard
heart-rate lowering therapies [8, 11]. In ERATO, as well as
in other studies, dronedarone was associated with a low risk
of proarrhythmia, including torsades de pointes [8–10].
The ANDROMEDA (ANtiarrhythmic trial with DRO-
nedarone in Moderate to severe congestive heart failure
Evaluating morbidity DecreAse) study, conducted in patients
with recent hospitalization due to severe heart failure (HF),
was prematurely stopped because of a higher number of
deaths in the dronedarone group at the time of an intermediate
safety analysis [12]. The ATHENA (A placebo-controlled,
double-blind, parallel arm Trial to assess the efficacy of
dronedarone 400 mg bid for the prevention of cardiovascular
Hospitalization or death from any cause in patiENts with
Atrial fibrillation/atrial flutter) study, which excluded
patients with New York Heart Association (NYHA) class
IV or recently decompensated HF, showed a significant
reduction in the combined endpoint of cardiovascular
hospitalizations or death with dronedarone in patients with
AF [14]. Dronedarone was approved by the US Food and
Drug Administration in July 2009 to reduce the risk of
cardiovascular hospitalization in patients with paroxysmal or
persistent AF or atrial flutter, with a recent episode of AF/
atrial flutter and associated cardiovascular risk factors, who
are in sinus rhythm or who will be cardioverted [15]. It is
contraindicated in patients with NYHA class IV HF, or
NHYAclassII–IIIHFwitharecentdecompensationrequiring
hospitalization or referral to a specialized HF clinic.
During the early course of development of dronedarone,
an ascending dose study was specifically designed to look
at tolerability in patients with compensated HF, with severe
left ventricular (LV) dysfunction. This paper reports the
findings from this study.
Methods
This double-blind, randomized, placebo-controlled, dose-
escalating study in three sequential groups was conducted
in 12 US centers between June 1996 and March 1998. All
patients gave written informed consent to participate in the
study, which was approved by local institutional review
boards and conducted in accordance with the Helsinki
principles [16] and Guidelines for Good Clinical Practice.
Patients Patientsaged18–75ywhometthefollowingcriteria
were eligible for inclusion in the study: in sinus rhythm;
impaired LV systolic function (LV ejection fraction [LVEF]
≤30%), documented with radionuclide ventriculography
(multiple uptake gated acquisition [MUGA] scan), echocar-
diography, or ventricular angiogram during the screening
phase of the study and confirmed with a radionuclide
ventriculography at baseline; known dilated cardiomyopathy
of any cause; and HF (NYHA class I–II) stable during the
previous 2 months. Patients were selected 1 month to 2 weeks
before study entry.
The main exclusion criteria were as follows: evidence of
clinically relevant hematologic, hepatic, gastrointestinal, renal,
pulmonary, endocrinologic, or psychiatric disease; clinical
evidence of acute HF under optimal treatment with
angiotensin-converting enzyme (ACE) inhibitors and diuretics;
unstable angina, recent myocardial infarction (≤3m o n t h s ) ,
atrioventricular block (second degree or more); history of
ventricular tachycardia or ventricular fibrillation necessitating
chronic treatment with antiarrhythmic agents; uncontrolled
hypertension; abnormal laboratory tests; females of child-
bearing potential; concomitant therapy with antiarrhythmic
agents, beta-blockers, verapamil, diltiazem, tricyclic antide-
pressants, anticonvulsants, or phenothiazines. Patients were
allowed to receive cardiac glycosides, diuretics, ACE inhib-
itors, and nitrates, provided the doses were kept constant during
the 14 days preceding the study and throughout the study.
Treatment Patients were randomized in a 2:1 ratio in three
sequential groups to receive dronedarone (400 mg once daily,
800 mg once daily, or 600 mg twice daily) or placebo for
30 days. Before progression to the next-dose step a safety
committee blinded to treatment allocation assessed the safety
endpoints (walking distance, LVEF, and NYHA status).
Evaluation criteria The primary objective was to assess the
effects of dronedarone on functional capacity, measured
during a standardized 6 min walk test of submaximal
exercise capacity [17] at Days 8 and 30.
Secondary objectives were to assess the effects of
dronedarone on LVEF and cardiothoracic ratio, as assessed
byradionuclideventriculographyandchestx-ray,respectively,
at baseline and on Day 30.
The effects of dronedarone on NYHA status, hepatic and
renal function, and Holter parameters (premature ventricular
contraction counts, arrhythmic events, heart rate, and QT
variability) were assessed. Twelve-lead electrocardiogram
(ECG) measurements (heart rate; QT, corrected QT [QTc],
andPRintervals)wererecordedonDays1,8,and30pre-dose
a n d4hp o s t - d o s e ;a n do nD a y s1 5a n d2 2p o s t - d o s ea tt i m eo f
study visit and at the post-study visit (Day 38). Holter
measurements were recorded over 24 h on Day 0 and over
48 h on Days 1/2, 8/9, and 29/30.
Patients underwent clinical examination at scheduled visits
on Days 1, 2, 8, 9, 15, 22, 29, 30, and 38. Clinical laboratory
parameters (hematology, biochemistry, and urinalysis) were
measured at screening, baseline, and on Days 8, 30, and 38,
450 Cardiovasc Drugs Ther (2010) 24:449–458and vital signs were monitored at scheduled visits. Adverse
events were assessed at each scheduled visit and coded
accordingtotheWorldHealthOrganizationAdverseReaction
Terminology.
Statistical methods The statistical analyses included data
for all patients who were randomized to treatment. Safety
analyses included all available data for all patients. The
main safety and efficacy parameters for the treatment
groups were compared at baseline, using analysis of
variance (ANOVA) or Kruskal-Wallis test according to the
variable distribution for quantitative parameters, and the
Fisher’s exact test when relevant. The frequency and
percentage of patients with at least one adverse event were
recorded by treatment. Statistical analyses of clinical data
were performed using SAS software (Version 6–09; SAS
Institute Inc, Cary, NC, USA).
Walking distance, LVEF, and cardiothoracic ratio were
measured at baseline, and changes from baseline were
calculated at each subsequent time point (walking distance,
Days 8 and 30; LVEF and cardiothoracic ratio, Day 30).
Changes from baseline were analyzed by ANOVA.
Equivalence of dronedarone doses and placebo was
concluded if the 90% confidence intervals (CIs) were
entirely within the reference interval (walking distance,
0.85–1.15; LVEF and cardiothoracic ratio, 0.80–1.20).
The mean difference of the measurement of walking
distance on Day 8 and Day 30 vs. placebo was calculated
(see Table 2, fourth column) as well as the 90% confidence
interval (see Table 2, fifth column). The difference was
calculated with respect to placebo in order to take into
account a potential placebo effect during the study (for
example a “training effect” due to the walking test itself). A
potential decrease in walking distance was considered
significant if the lower limit of the 90% confidence interval
was >15% the baseline value (i.e. >60.7 m). In terms of
safety analyses, individual values that were outside the
normal laboratory range and predefined marked increases
and decreases from baseline were noted. In addition,
patients with high QTc intervals (QTc >450 ms for
men, >470 ms for women) were identified.
The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agree to the manuscript as written.
Results
Of the 247 patients who were screened before the start of the
study, 124 were randomized to treatment (29 dronedarone
400 mg, 30 dronedarone 800 mg, 25 dronedarone 1,200 mg,
40 placebo; Fig. 1). The main reasons 123 patients were not
randomized to treatment included no current impairment of
LV function (95 patients) and abnormal laboratory tests (54
patients). A total of 111 patients completed the study (27
dronedarone 400 mg, 27 dronedarone 800 mg, 19 dronedar-
one 1,200 mg, 38 placebo); 13 patients withdrew from the
study, and the reasons for withdrawal are detailed in Fig. 1.
Baseline characteristics At baseline, demographic charac-
teristics, walking distance, LVEF, and cardiothoracic ratio
were comparable among the treatment groups (Table 1).
Concomitant medication usage was equally distributed across
the treatment groupsand was inline withrecommendations at
the time the study was conducted.
Additional baseline analyses demonstrated that the
treatment groups were similar in terms of duration and
physical symptoms of HF (results not shown).
Exercise capacity No significant difference was reported
among treatment groups with respect to the primary
endpoint of walking distance during the 6 min test,
indicating no decrease in exercise capacity on Days 8 and
30 (Table 2). The mean walking distances in the dronedar-
one 400 mg and 800 mg groups were equivalent to placebo
on Days 8 and 30 (Table 2). The results of the analysis of
the mean values for walking distance at different timepoints
are shown in Fig. 2.
LVEF and cardiothoracic ratio
The difference in mean LVEF for each dronedarone treatment
group compared with placebo on Day 30, along with the
respective 90% confidence intervals, are shown in Fig. 3.
No significant differences for LVEF on Day 30 were
noted among treatment groups (Fig. 3; dose effect from
ANOVA on observed values=0.37). The cardiothoracic
ratio was similar in all treatment groups at baseline and
throughout treatment.
NYHA status The majority of patients did not experience
any change in NYHA status during treatment compared
with baseline. A total of 7/84 patients receiving dronedar-
one and 4/40 receiving placebo had changes in NYHA
status while on treatment; however, no trends between the
changes and treatment were detected. One patient in the
dronedarone 400 mg group, treated until Day 30, had an
increase in NYHA status from class I at baseline to class IV
(on Day 38) in the context of angina pectoris and acute
myocardial infarction leading to death on Day 42.
Electrophysiological activity The heart rate–lowering
properties of dronedarone were confirmed by the ECG
and Holter measurements. A moderate decreasewas observed
Cardiovasc Drugs Ther (2010) 24:449–458 451in mean heart rate with dronedarone 800 mg and 1,200 mg,
togetherwitha moderateincreaseinmean PR interval, and no
significant change in mean QRS and QTc intervals compared
with baseline on Day 30 at 4 h post-dosing. Mean changes
from baseline in heart rate on Day 30 (4 h post-dosing)
were −6 . 5( s t a n d a r de r r o ro ft h em e a n[ S E M ]2 . 0 )b e a t s /
min (p=0.0037) and −8.5 (SEM 3.3) beats/min (p=0.019)
in the dronedarone 800 mg and 1,200 mg groups,
respectively. Heart rate returned to baseline values on
Day 38, 1 week after dronedarone discontinuation, with no
evidence of a rebound phenomenon.
Mean changes from baseline in PR interval on Day 30
(4 h post-dosing) were 9.6 (SEM 3.8) ms (p=0.0193) and
12.9 (SEM 4.2) ms (p=0.0076) in the dronedarone 800 mg
and 1,200 mg groups, respectively. For the placebo and
dronedarone 400 mg groups, none of the changes from
baseline were significant.
A significant dose-related decrease in average heart rate
was observed with the Holter measurements (Fig. 4). A
significant decrease in the number of supraventricular
extrasystoles was observed during daytime at the end of
the treatment period (Days 29–30) in the dronedarone
1,200 mg group (p=0.005). A pronounced decrease in
ventricular extrasystoles was observed in two patients in the
1,200 mg group during the daytime at the end of the
treatment period (Days 29–30).
Adverse events The global incidence of treatment-emergent
adverse events (defined as all adverse events after the first
dronedarone dose) was 61.9% with dronedarone and 72.5%
with placebo. Cardiovascular adverse events were reported in
13/84 (15.5%) dronedarone patients overall, but in 4/30
(13.3%) of those taking 800 mg once daily and in 4/40
(10.0%) placebo patients. These events included cardiac
failure, hypotension, hypertension, ECG abnormalities, and
edema. With respect to cardiac failure no evidence of a dose
effectwasobservedastheseeventsoccurredin3/29,1/30,and
2/25 patients in the dronedarone 400, 800, and 1,200 mg
groups, respectively, and also in 2/40 patients in the placebo
group. However, due to the small patient numbers in each
group the interpretation of this finding is limited. A prolonged
QT/QTc was observed in two patients who received drone-
darone (2.4%; QT/QTc=540/561 and 560/566 ms) both in the
1,200 mg group. Importantly, no torsades de pointes was
Patients screened
N=247
Randomized
n=124
Not randomized
n=123 
No impairment of 
left ventricular function
n=95 
Abnormal laboratory tests
n=54
Withdrew (n=13)
Adverse events (n=6)
  Dronedarone 400 mg (n=1)
  Dronedarone 800 mg (n=1)
  Dronedarone 1,200 mg (n=3)
  Placebo (n=1)
Death (n=1)
  Dronedarone 1,200 mg
Other (n=6)
  Dronedarone 400 mg (n=1)
  Dronedarone 800 mg (n=2)
  Dronedarone 1,200 mg (n=2)
  Placebo (n=1)
Dronedarone 400 mg
n=29
Dronedarone 800 mg
n=30
Dronedarone 1,200 mg
n=25
Placebo
n=40
Dronedarone 400 mg
n=27
Dronedarone 800 mg
n=27
Dronedarone 1,200 mg
n=19
Placebo
n=38
Completed study
n=111
Fig. 1 Patient disposition
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Holter monitoring. Thirteen patients (10 dronedarone, three
placebo) experienced 22 serious adverse events (Table 3).
Eighteen of the 22 events were considered unrelated or
unlikely to be related to treatment. A total of 12 adverse
events led to discontinuation of treatment in seven patients (one
placebo, one dronedarone 400 mg, two dronedarone 800 mg,
three dronedarone 1,200 mg). Three deaths occurred during or
after completion of the study (Table 3). One death occurred
during the study in a patient receiving dronedarone 1,200 mg;
this patient with severe ischemic cardiomyopathy, HF, and
diabetes mellitus died suddenly on Day 17. No ventricular
arrhythmia or any QTc prolongation was documented during
treatment with the study drug. In addition, two deaths occurred
after completion of the study in patients receiving dronedarone
400 mg and 800 mg; they occurred 12 and 26 days after the
end of treatment with the study drug. The first death occurred
in a patient with triple vessel coronary artery disease. The
second death occurred in a patient with dilated cardio-
myopathy and a history of HF. The relationships with the
study drug were reported as unlikely by the investigators.
No significant differences were observed between
treatment groups for hematologic or biochemistry parame-
ters. No thyroid disorders were reported during the study,
and no clinically relevant changes were noted in hepatic or
renal parameters.
Discussion
Arrhythmias are common in patients with severe systolic
dysfunction, and it is important to determine if treatments
are well tolerated in this population. The main objective of
this randomized study was to investigate the effects of
dronedarone on functional capacity, as assessed by exercise
capacity, in patients with severe LV dysfunction and
compensated HF. Dronedarone (400 mg, 800 mg, or
1,200 mg daily) did not decrease functional capacity in
Table 1 Demographic and baseline characteristics (Data are mean (SD) unless otherwise stated)
Parameter Placebo Dronedarone Total
400 mg 800 mg 1,200 mg
n=40 n=29 n=30 n=25 N=124
Age, y 57.1 (9.5) 56.3 (9.0) 57.5 (9.8) 57.3 (10.5) 57.0 (9.5)
Weight, kg 87.04 (17.44) 83.60 (12.62) 91.56 (18.15) 88.98 (20.58) 87.72 (17.35)
Race, n (%)
Caucasian 22 (55) 20 (69) 21 (70) 16 (64) 79 (64)
Black 18 (45) 7 (24) 9 (30) 9 (36) 43 (35)
Other – 2 (7) ––2 (2)
Sex, n (%)
Male 33 (83) 27 (93) 26 (87) 24 (96) 110 (89)
Female 7 (18) 2 (7) 4 (13) 1 (4) 14 (11)
Walking distance during 6 min exercise test, meters 393.4 (115.7) 417.0 (114.7) 398.9 (62.2) 415.3 (142.8) 404.6 (110.7)
LVEF, % 23.4 (5.2) 24.5 (4.7) 24.4 (4.2) 23.4 (6.1) 23.9 (5.0)
Cardiothoracic ratio, % 54.3 (7.0) 53.1 (7.5) 55.6 (6.8) 53.3 (4.7) 54.1 (6.7)
NYHA status, n (%)
I 10 (25) 15 (52) 6 (20) 3 (12) 34 (27)
II 30 (75) 14 (48) 24 (80) 22 (88) 90 (73)
Concomitant medication, n (%)
ACE inhibitors or ARBs 37 (92.5) 28 (96.6) 29 (96.7) 22 (88.0) 116 (93.5)
Diuretics 37 (92.5) 26 (89.7) 25 (83.3) 22 (88.0) 110 (88.7)
Digitalis 30 (75.0) 23 (79.3) 23 (76.7) 22 (88.0) 98 (79.0)
Chronic antiplatelet therapy 24 (60.0) 15 (51.7) 15 (50.0) 11 (44.0) 65 (52.4)
Oral anticoagulant 12 (30.0) 11 (37.9) 8 (26.7) 11 (44.0) 42 (33.9)
Statins 11 (27.5) 10 (34.5) 9 (30.0) 8 (32.0) 38 (30.6)
NSAIDs 3 (7.5) 1 (3.4) 1 (3.3) 1 (4.0) 6 (4.8)
Beta-blockers 1 (2.5)
a 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
ARB angiotensin II receptor blocker; NSAID nonsteroidal anti-inflammatory drug
aPatient was receiving beta-blocker treatment concomitantly and should have been excluded. This was considered an investigator protocol deviation
Cardiovasc Drugs Ther (2010) 24:449–458 453this patient population. This finding was consistent with the
results from the ERATO study, in which dronedarone
400 mg twice daily decreased heart rate during submaximal
and maximal exercise, without a reduction in exercise
tolerance, in patients with permanent AF receiving standard
treatments [8]. In the present study, LVEF was measured at
baseline and on therapy, and no significant differences in
LVEF were observed. Likewise there was no significant
effect of therapy on cardiothoracic ratio. Dronedarone did
not adversely impact functional capacity as measured by
NYHA classification.
Another interesting aspect of this study is the significant,
dose-dependent reduction in heart rate with dronedarone.
The reduction in heart rate could be related to the calcium
antagonist, the antiadrenergic properties of dronedarone, or
possibly the inhibiting effect on the If current which has
been reported in animal models [18]. Whether the benefi-
cial effects on outcomes reported with dronedarone in the
ATHENA study could have been partially related to heart
rate reduction is speculative at present [14]. However,
interventions associated with heart rate reduction have been
reported to improve outcomes [19].
Table 2 Mean walking distance (meters) during 6 min exercise test at baseline and during treatment with dronedarone 400 mg, 800 mg, 1,200 mg
daily, or placebo
Visit Treatment group Mean (SD) Difference vs. placebo 90% CI of difference ANOVA
a
Mean walking distance (meters)
Day 0 (n=124) Placebo 393.4 (115.7) NA NA 0.7842
Dronedarone 400 mg 417.0 (114.7) NA NA
Dronedarone 800 mg 398.9 (62.2) NA NA
Dronedarone 1,200 mg 415.3 (142.8) NA NA
All 404.6 (110.7) NA NA
Day 8 (n=118) Placebo 411.0 (123.4) NA NA 0.8705
Dronedarone 400 mg 414.9 (102.3) 3.92 −41.55/49.39
Dronedarone 800 mg 408.0 (59.2) −2.94 −40.30/34.42
Dronedarone 1,200 mg 431.5 (128.8) 20.50 −34.34/75.35
Day 30 (n=113) Placebo 421.6 (113.8) NA NA 0.8502
Dronedarone 400 mg 445.1 (120.9) 23.51 −25.35/72.36
Dronedarone 800 mg 421.0 (55.5) −0.64 −35.71, 34.43
Dronedarone 1,200 mg 430.0 (165.0) 8.44 −58.11, 74.99
NA not applicable
aDose effect from ANOVA on observed values
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consideration given the proarrhythmia or end-organ toxicity
of currently available treatments [20]. In the present study
dronedarone was well tolerated, with 11/84 patients
discontinuing treatment with dronedarone compared with
2/40 patients in the placebo group. The incidence of
adverse events was low in patients receiving dronedarone,
with no dose effect, and often similar incidence in the
placebo group, indicating that the events observed were
part of the natural history of the disease rather than a side
effect of treatment. The safety data were consistent with the
known profile of dronedarone [8–10, 14]. In terms of
cardiovascular adverse events, there were no reports of new
arrhythmic events, which may be supportive of an absence
of a proarrhythmic effect or of torsades de pointes. This
finding concurs with only one report of torsades de pointes
with dronedarone in the development program overall,
which included nearly 3,500 patients who received drone-
darone. That event occurred in a patient in the ATHENA
study who had additional risk factors for torsades de
pointes (QTc at baseline of 522 ms and episodes of severe
bradycardia). No thyroid disorders or liver abnormalities
were reported in the present study.
Spontaneous sudden death is generally high in this patient
population, and two of the three deaths in this study occurred
12 and 26 days after discontinuation of dronedarone, the
elimination half-life of which is 24 h [6]. Drug-related
exacerbation of HF was not evident in this study. The
ANDROMEDA study investigated the long-term effects of
dronedarone in hospitalized patients with symptomatic
decompensated HF and severe LV dysfunction, specifically
to demonstrate that dronedarone does not increase mortality
in these patients [12]. Patients were to be randomly assigned
to dronedarone 400 mg twice daily or placebo [12]. During a
median follow-up of 2 months, more deaths were observed
in the dronedarone group than in the placebo group (25
patients [8.1%] vs. 12 patients [3.8%], respectively). The
excess mortality in the dronedarone group was largely due to
worsening HF (10 dronedarone, two placebo). This
imbalance in mortality rates led the data and safety
monitoring board to recommend early trial discontinuation
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[12] .T h eu n s t a b l en a t u r eo ft h e s ep a t i e n t sh a sb e e n
identified as a potential factor in these findings, although
the possibility that this was a chance finding cannot be ruled
out [13].
In the present study there was no evidence that
dronedarone had a deleterious effect on clinical parameters
and LVEF, assessed by a MUGA scan, which is a precise
and reliable measure.
Treatments to improve both the short- and long-term
outcomes of AF are needed. The present study has several
limitations. Firstly, the four groups were small and
treatment duration was relatively short, making it difficult
to draw safety conclusions. Secondly, the study was
conducted at a time when beta-blockers were not recom-
mended in patients with HF and it could therefore be
considered that the patients were not optimally treated.
Thirdly, a 6 min walk test was the only crude parameter
used to evaluate the effect of the drug on exercise capacity
in the study. Finally, as this study was conducted more than
10 years ago it could be considered of little interest today.
However, this study provides important information with
particular regard to potential changes in functional capacity
and LVEF measurements after initiation of dronedarone
treatment in patients with severe LV dysfunction. This
study also examined dronedarone treatment at several
different dosage levels (400–1,200 mg/day), thereby
providing data on levels within and outside of the current
recommended dosages. On entry to this study patients were
asymptomatic and fully functional following aggressive
ACE inhibitor therapy. It is important to point out that
although beta-blockers are now indicated for patients with
Table 3 No. of subjects with at least one serious adverse event with dronedarone 400 mg, 800 mg, 1,200 mg daily, or placebo
Serious adverse events No. of subjects with at least one adverse event (no. of adverse events), %
Placebo Dronedarone
400 mg 800 mg 1,200 mg
n=40 n=29 n=30 n=25
Any class, any event 3 (4) 7.5 3 (5) 10.3 4 (4) 13.3 3 (9) 12.0
Body as a whole
Chest pain 1 (1) 2.5 – 1 (1) 3.3 2 (2) 8.0
Sudden death –– 1 (1) 3.3
a 1 (1) 4.0
b
Chest pain substernal – 1 (1) 3.4 ––
Fatigue –– – 1 (1) 4.0
Alcohol intolerance 1 (1) 2.5 –––
Cardiovascular disorders
Cardiac failure – 1 (1) 3.4
a 1 (1) 3.3 –
Cardiac failure left 1 (1) 2.5 –––
Hypertension 1 (1) 2.5 –––
Gastrointestinal system
Abdominal pain –– – 1 (1) 4.0
Diarrhea –– – 1 (1) 4.0
Heart rate and rhythm disorders
Extrasystoles – 1 (1) 3.4 ––
Musculoskeletal system disorders
Arthropathy –– 1 (1) 3.3 –
Myo-, endo-, and pericardial and valve disorders
Angina pectoris –– – 1 (1) 4.0
Platelet, bleeding, and clotting disorders
Gastrointestinal hemorrhage – 1 (1) 3.4 ––
Respiratory system disorders
Dyspnea –– – 2 (2) 8.0
Pulmonary carcinoma – 1 (1) 3.4 ––
aTwo deaths, one with severe coronary artery disease (dronedarone 400 mg) and one with severe dilated cardiomyopathy (dronedarone 800 mg), were
reported 12 and 26 days after the end of the study.
bOne sudden death was reported on Day 17 of the study in patient with severe ischemic cardiomyopathy,
congestive heart failure, and diabetes mellitus. There was no evidence of ventricular arrhythmia or corrected QT prolongation prior to death
456 Cardiovasc Drugs Ther (2010) 24:449–458stable HF, they were not considered the standard of care in
the mid- to late-1990s when this study was conducted.
To summarize, the results from this study show that
dronedarone (400 mg, 800 mg, or 1,200 mg daily) did not
affect exercise capacity and did not decrease LVEF in
patients with severe LV dysfunction and stabilized com-
pensated HF receiving other cardiovascular treatments.
Dronedarone decreased the heart rate and was well tolerated
with no proarrhythmic effects in this small cohort of
patients.
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Marion Mills, MD, University of Florida, Gainesville, FL,
USA; Pramod Mohanty, MD, VA Medical Center,
Richmond, VA, USA; Joel Michael Neutel, MD, Orange
County Research Center, Orange, CA, USA; Imran K.
Niazi, MD, Wisconsin Center for Clinical Research,
Milwaukee, WI, USA; Maria-Teresa Olivari, MD, Uni-
versity of Nebraska Medical Center, Omaha, NE, USA;
Carl Pepine, MD, University of Florida, Gainesville, FL,
USA; Jonathan Plehn, MD, Dartmouth Hitchcock Medi-
cal Center, Lebanon, NH, USA; Stephen Singh, MD,
Institute of Clinical Research, Washington VA Medical
Center, Washington, DC, USA.
References
1. Fuster V, Rydén LE, Cannom DS, et al. American College of
Cardiology; American Heart Association Task Force; European
Society of Cardiology Committee for Practice Guidelines;
European Heart Rhythm Association; Heart Rhythm Society.
ACC/AHA/ESC 2006 guidelines for the management of patients
with atrial fibrillation: full text: a report of the American College of
Cardiology/American Heart Association Task Force on practice
guidelines and the European Society of Cardiology Committee for
PracticeGuidelines(WritingCommitteetoRevisethe2001guidelines
for the management of patients with atrial fibrillation) developed in
collaboration with the European Heart Rhythm Association and the
Heart Rhythm Society. Europace. 2006;8:651–745.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an
independent risk factor for stroke: the Framingham Study. Stroke.
1991;22:983–8.
3. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The
natural history of atrial fibrillation: incidence, risk factors, and
prognosis in the Manitoba follow-up study. Am J Med.
1995;98:476–84.
4. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel
WB, Levy D. Impact of atrial fibrillation on the risk of death: the
Framingham heart study. Circulation. 1998;98:946–52.
5. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based
study of the long-term risks associated with atrial fibrillation:
20-year follow-up of the Renfrew/Paisley study. Am J Med.
2002;113:359–64.
6. Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs
Today (Barc). 2006;42:75–86.
7. Dale KM, White CM. Dronedarone: an amiodarone analog for the
treatment of atrial fibrillation and atrial flutter. Ann Pharmacother.
2007;41:599–605.
8. Davy JM, Herold M, Hoglund C, et al. ERATO Study Investigators.
Dronedarone for the control of ventricular rate in permanent atrial
fibrillation: the Efficacy and safety of dRonedArone for the cOntrol
ofventricularrateduringatrialfibrillation(ERATO)study.AmHeart
J. 2008;156:527–9.
9. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N,
Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a
dose-ranging study. Eur Heart J. 2003;24:1481–7.
10. Singh BN, Connolly SJ, Crijns HJ, et al. EURIDIS and ADONIS
Investigators. Dronedarone for maintenance of sinus rhythm in
atrial fibrillation or flutter. N Engl J Med. 2007;357:987–99.
11. Davy JM, Herold M, Hoglund C, Radzik D, Timmermans AJM.
Effect of dronedarone on exercise in patients with permanent atrial
fibrillation. Eur Heart J. 2006;1:885.
12. Kober L, Torp-Pedersen C, McMurray JJ, et al. Dronedarone
study group. Increased mortality after dronedarone therapy for
severe heart failure. N Engl J Med. 2008;358:2678–87.
13. Zimetbaum PJ. Dronedarone for atrial fibrillation–an odyssey. N
Engl J Med. 2009;360:1811–3.
14. Hohnloser SH, Crijns HJ, van Eickels M, et al. ATHENA
Investigators. Effect of dronedarone on cardiovascular events in
atrial fibrillation. N Engl J Med. 2009;360:668–78.
Cardiovasc Drugs Ther (2010) 24:449–458 45715. MULTAQ (dronedarone) tablets [prescribing information]. http://
products.sanofi-aventis.us/multaq/multaq.pdf. Accessed 8 Jan
2010.
16. World Medical Association Declaration of Helsinki. Ethical
principles for medical research involving human subjects. Hong
Kong. 1989.
17. Lipkin DP, Scriven AJ, Crake T, Poole-Wilson PA. Six minute
walking test for assessing exercise capacity in chronic heart
failure. Br Med J (Clin Res Ed). 1986;292:653–5.
18. Rocchetti M, Bertrand JP, Nisato D. Cellular electrophysiological
study of dronedarone, a new amiodarone-like agent, in guinea pig
sinoatrial node. Naunyn-Schmiedebergs Arch Pharmacol.
1998;358:R617.
19. Fox K, Borer JS, Camm AJ, et al. Heart rate working Group.
Resting heart rate in cardiovascular disease. J Am Coll Cardiol.
2007;50:823–30.
20. Patton KK, Page RL. Pharmacological therapy of atrial fibrilla-
tion. Expert Opin Investig Drugs. 2007;16:169–79.
458 Cardiovasc Drugs Ther (2010) 24:449–458